跳至主要内容
临床试验/EUCTR2018-003518-41-NL
EUCTR2018-003518-41-NL进行中(未招募)1 期

Efficacy of Diltiazem to improve coronary microvascular dysfunction: A randomized clinical trial - EDIT-CMD

Radboudumc0 个研究点目标入组 142 人开始时间: 2019年7月26日最近更新:
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
发起方
Radboudumc
入组人数
142

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

入选标准

  • 1.Patients above the age of 18.
  • 2.Patients with chronic angina, defined as symptoms of angina at least 2 times a week despite medical therapy for the last 3 months.
  • 3.No signs of obstructive coronary artery disease (CAD), documented within 5 years* before inclusion by one of the following modalities:
  • a.Coronary angiography: patients with non-obstructive (<50% stenosis) coronary arteries are eligible, or patients with intermediate stenosis (between 50 and 70%) with documented FFR >0.80 or iFR >0.89 on angiogram. In patients with a history of stenting are eligible if they have no current significant coronary epicardial stenoses, a minimum diameter stenosis of <10% is required.
  • b.Coronary computed tomography angiography (CCTA) with finding of non-obstructive coronary arteries
  • 4.Baseline coronary reactivity testing with at least one of the following:
  • a.CFR = 2.0
  • b.IMR = 25
  • c.Abnormal acetylcholine test defined as the presence of (recognizable) angina, ischemic ECG abnormalities with or without epicardial spasm
  • 5.Signed written informed consent
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 100
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 42

排除标准

  • 1.Other cause of angina deemed highly likely by the treating physician.
  • 2.Active use of non-dihydropyridine calcium channel blockers or any use of non-dihydropyridine calcium channel blockers in the previous month or known intolerance for non-dihydropyridine calcium channel blockers.
  • 3.Left ventricular ejection fraction < 50%.
  • 4.Recent PCI within the past 3 months.
  • 5.Patients with history of coronary artery bypass grafting (CABG).
  • 6.Surgically uncorrected significant congenital or valvular heart disease, cardiomyopathy or myocarditis.
  • 7.Significant renal impairment (eGFR < 30).
  • 8.Significant hepatic impairment (history or cirrhosis or abnormal serum ALT or AST 3-fold greater than the upper limit of normal).
  • 9.Pregnant women or women of child bearing potential who are planning to become pregnant within the next 3 months.
  • 10.Prior non-cardiac illness with an estimated life expectancy < 1 year.
  • 11.Contra-indication to coronary reactivity testing:
  • a.Contraindication or known hypersensitivity to adenosine.
  • b.Contraindication or known hypersensitivity to acetylcholine.
  • c.Contraindication to aminophylline.
  • d.Ongoing dipyridamole treatment.
  • 12.Contra-indication for treatment with CCB: second or third degree AV block, sinus node dysfunction and/or bradycardia (heart rate < 40 beats/minute)
  • 13.Symptomatic hypotension or systolic BP < 100 mmHg at screening visit on 2 consecutive measurements.
  • 14.History of hospitalization for asthma and/or current use of = 2 types of pulmonary medications for asthma and/or severe COPD with FEV1 < 50% of predicted.
  • 15.Participation in another clinical study with an IMP during the lastwithin one month prior to enrollment.
  • 16.Inability of the patient, in the opinion of the investigator, to understand and/or comply with study medications, procedures and/or follow-up OR any conditions that, in the opinion of the investigator, may render the patient unable to complete the study.
  • 17.Unable to give informed consent (i.e. due to language barrier).

研究者

发起方
Radboudumc

相似试验